A 74-year-old woman came to the office with a 5month history of dizziness. Her symptoms began as she was writing one morning before breakfast. She said that suddenly "everything was spinning" and "everything was draining from my body." She fell to the floor and experienced nausea and vomiting, but she did not lose consciousness. She was hospitalized, but the spinning feeling persisted for 3 more days. It was eventually alleviated by meclizine. Upon discharge, she noted an occasional lack of balance, but the spinning feeling did not return. She came to the author's office for evaluation because she continued to experience an occasional lack of balance while standing and because she was unable to walk a straight line. Her unsteadiness became worse when she was fatigued. She experienced no such feeling when she was sitting or lying down.
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ADVERSE REACTIONS
In Phase 3 clinical trials, a total of 564 patients were treated with CIPRO-HC OTIC. Adverse events with at least remote relationship to treatment Included headache (1.2%) and pruritus (0.4%). The following treatment-related adverse events were each reported In a single patient migraine, hypesthesia, pareslhesia, fungal dermatttis. cough, rash, urticaria, and alopecia NDC 0065-8531-10 CIPRO-Is a registered trademark of Bayer AG. Ucensed by Bayer AG Manufactured by Bayer Corporation Rx Only U. S. Pal Nos. 4,670,444; 4,844,902; 5,843,930; and Pal Pending. Revised January, 1999 CHCOB-0199 References:
. Evaluation of her acoustic stapedial reflexes revealed a cochlear or inner-ear-sensation level response. Ultrathinsection computed tomography of the temporal bones detected sclerotic plaque at the poles of the oval window. The pericochlear lucency was questionable, and the right footplate was thickened at the anterior pole. A 5-hour glucose tolerance test resulted in a normal fasting blood sugar level followed by diabetic levels through the third hour as well as evidence ofhyperinsulinemia through the third hour. Her triglyceride level was still elevated. The patient was prescribed a bisphosphonate and a calcium supplement to address her otosclerosis and placed on a diet to address her metabolic factors. After 3 months, she reported that she felt steadier on her feet and did not weave as much, and that she experienced less fatigue. She continued to experience occasional tinnitus and aural fullness in her left ear. A follow-up sinusoidal verticalaxis rotation test elicited phase responses consistent with a peripheral vestibular disorder as well as a mild asymmetry. A 2-hour postprandial blood test revealed that her blood glucose and insulin levels were normal.
She was encouraged to discontinue the lorazepam, and her symptoms gradually diminished. Sodium fluoride was added to her regimen. She tried vestibular rehabilitation therapy, but she felt that it was of limited benefit. Three years after her initial visit, she remained free of symptoms.
